Search details
1.
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Int J Cancer
; 154(6): 1043-1056, 2024 Mar 15.
Article
in English
| MEDLINE | ID: mdl-37994647
2.
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Liver Int
; 44(1): 113-124, 2024 01.
Article
in English
| MEDLINE | ID: mdl-37789669
3.
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
Hepatol Res
; 54(4): 382-391, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-37983642
4.
Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents.
J Gastroenterol Hepatol
; 2024 Apr 11.
Article
in English
| MEDLINE | ID: mdl-38602340
5.
Increased Spleen Volume in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab in Comparison to Lenvatinib: A Retrospective Analysis.
Oncology
; 101(3): 193-202, 2023.
Article
in English
| MEDLINE | ID: mdl-36649691
6.
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Oncology
; 101(4): 270-282, 2023.
Article
in English
| MEDLINE | ID: mdl-36455517
7.
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
Oncology
; 101(10): 624-633, 2023.
Article
in English
| MEDLINE | ID: mdl-37307798
8.
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
Oncology
; 101(9): 542-552, 2023.
Article
in English
| MEDLINE | ID: mdl-37552968
9.
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.
Oncology
; 101(5): 283-291, 2023.
Article
in English
| MEDLINE | ID: mdl-36657420
10.
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis.
Hepatol Res
; 53(8): 737-748, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37020416
11.
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Hepatol Res
; 53(10): 1031-1042, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-37306040
12.
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
J Gastroenterol Hepatol
; 38(8): 1389-1397, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37231943
13.
Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era.
Oncology
; 100(2): 65-73, 2022.
Article
in English
| MEDLINE | ID: mdl-34844247
14.
Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study.
Oncology
; 100(8): 449-459, 2022.
Article
in English
| MEDLINE | ID: mdl-35816996
15.
Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
Oncology
; 100(12): 645-654, 2022.
Article
in English
| MEDLINE | ID: mdl-36103846
16.
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis.
Hepatol Res
; 52(5): 462-470, 2022 May.
Article
in English
| MEDLINE | ID: mdl-35080087
17.
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis.
Hepatol Res
; 52(3): 308-316, 2022 Mar.
Article
in English
| MEDLINE | ID: mdl-34799975
18.
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice.
Hepatol Res
; 52(9): 773-783, 2022 Sep.
Article
in English
| MEDLINE | ID: mdl-35633504
19.
[Liver injury in patients with moderate II COVID-19 who received dexamethasone monotherapy].
Nihon Shokakibyo Gakkai Zasshi
; 119(4): 332-341, 2022.
Article
in Japanese
| MEDLINE | ID: mdl-35400686
20.
Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study.
Oncology
; 99(10): 641-651, 2021.
Article
in English
| MEDLINE | ID: mdl-34515171